JP2013531801A - 標的検出のためのハプテンコンジュゲート - Google Patents

標的検出のためのハプテンコンジュゲート Download PDF

Info

Publication number
JP2013531801A
JP2013531801A JP2013518768A JP2013518768A JP2013531801A JP 2013531801 A JP2013531801 A JP 2013531801A JP 2013518768 A JP2013518768 A JP 2013518768A JP 2013518768 A JP2013518768 A JP 2013518768A JP 2013531801 A JP2013531801 A JP 2013531801A
Authority
JP
Japan
Prior art keywords
hapten
conjugate
antibody
peroxidase
subsequent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531801A5 (enExample
Inventor
アドリアン， イー． ムリーリョ，
ジェローム， ダブリュ． コスメーダー，
エリック メイ，
ウィリアム デイ，
マーク ラフィーバー，
アン， エム． ペダータ，
クリストファー ビーニアーツ，
フィリップ ミラー，
Original Assignee
ヴェンタナ メディカル システムズ， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェンタナ メディカル システムズ， インク． filed Critical ヴェンタナ メディカル システムズ， インク．
Publication of JP2013531801A publication Critical patent/JP2013531801A/ja
Publication of JP2013531801A5 publication Critical patent/JP2013531801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2013518768A 2010-07-02 2011-07-01 標的検出のためのハプテンコンジュゲート Pending JP2013531801A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39894610P 2010-07-02 2010-07-02
US61/398,946 2010-07-02
US201161464216P 2011-02-28 2011-02-28
US61/464,216 2011-02-28
PCT/US2011/042849 WO2012003476A2 (en) 2010-07-02 2011-07-01 Hapten conjugates for target detection

Publications (2)

Publication Number Publication Date
JP2013531801A true JP2013531801A (ja) 2013-08-08
JP2013531801A5 JP2013531801A5 (enExample) 2014-07-17

Family

ID=44583735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518768A Pending JP2013531801A (ja) 2010-07-02 2011-07-01 標的検出のためのハプテンコンジュゲート

Country Status (6)

Country Link
US (1) US20130109019A1 (enExample)
EP (1) EP2588443A2 (enExample)
JP (1) JP2013531801A (enExample)
AU (1) AU2011274369A1 (enExample)
CA (1) CA2800936A1 (enExample)
WO (1) WO2012003476A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514214A (ja) * 2012-03-27 2015-05-18 ヴェンタナ メディカル システムズ， インク． シグナリングコンジュゲート及び使用法
JP2017158497A (ja) * 2016-03-10 2017-09-14 コニカミノルタ株式会社 Ｆｉｓｈ染色方法
WO2017175523A1 (ja) * 2016-04-06 2017-10-12 コニカミノルタ株式会社 蛍光免疫染色法
JPWO2016147825A1 (ja) * 2015-03-13 2017-12-28 シスメックス株式会社 被検物質の検出方法およびその方法に用いられる試薬キット
JP2018536163A (ja) * 2015-11-22 2018-12-06 ヴェンタナ メディカル システムズ， インク． Ｐｄ−ｌ１陽性腫瘍組織における免疫細胞を同定する方法
JP2020514701A (ja) * 2016-12-19 2020-05-21 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
JP2022500657A (ja) * 2018-09-20 2022-01-04 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本
JP2023538753A (ja) * 2020-08-28 2023-09-11 ヴェンタナ メディカル システムズ， インク． 検出可能な部分を含むコンジュゲート

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10267769B2 (en) 2010-03-04 2019-04-23 Ventana Medical Systems, Inc. Processing system for processing specimens using acoustic energy
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
WO2012003478A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
WO2013167387A1 (en) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2
WO2014048942A1 (en) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Probes for pten, pik3ca, met, and top2a, and method for using the probes
JP6576835B2 (ja) * 2013-03-12 2019-09-18 ヴェンタナ メディカル システムズ， インク． 標的物をｉｎｓｉｔｕ検出するための近接アッセイ
ES2804300T3 (es) 2013-03-12 2021-02-05 Ventana Med Syst Inc Microscopía mejorada digitalmente para histología multiplexada
AU2014230469B2 (en) * 2013-03-15 2017-07-13 Ventana Medical Systems, Inc. Spectral unmixing
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
CN110669826B (zh) 2013-04-30 2025-01-07 加州理工学院 通过顺序杂交编条形码的分子多重标记
ES2729638T3 (es) * 2013-10-11 2019-11-05 Ventana Med Syst Inc Ensayos múltiplex de tinción conjunta de receptores de HER2 y de estrógenos para detectar heterogeneidad tumoral
EP3617322A1 (en) 2014-02-24 2020-03-04 Ventana Medical Systems, Inc. Automated rna detection using labeled 2 -o-methyl rna oligonucleotide probes and signal amplification systems
DK3149042T3 (da) 2014-05-29 2019-11-04 Spring Bioscience Corp PD-L1-antistoffer og anvendelser deraf
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
RU2743169C2 (ru) 2015-11-06 2021-02-15 Вентана Медикал Системз, Инк. Репрезентативная диагностика
JP6876062B2 (ja) 2016-01-26 2021-05-26 ヴェンタナ メディカル システムズ， インク． 自動ダイセクション、次世代シークエンシング、及び自動スライド染色装置を用いる、腫瘍のための予測診断ワークフロー
AU2017229370B2 (en) 2016-03-08 2021-03-11 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
EP3475701B1 (en) 2016-06-28 2023-02-22 Ventana Medical Systems, Inc. New colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates
WO2018055014A1 (en) 2016-09-23 2018-03-29 Ventana Medical Systems, Inc. Methods and systems for scoring extracellular matrix biomarkers in tumor samples
EP3659110A1 (en) 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
EP3710820B1 (en) 2017-11-13 2025-06-11 F. Hoffmann-La Roche AG Devices for sample analysis using epitachophoresis
ES2965647T3 (es) 2018-01-31 2024-04-16 Ventana Med Syst Inc Procedimientos y sistemas para la evaluación de infiltrado de células inmunitarias en cáncer colorrectal en estadio III
WO2019224153A1 (en) 2018-05-21 2019-11-28 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
CN108918896A (zh) * 2018-05-29 2018-11-30 郑州左安检测科技有限公司 一种检测苯二氮卓的fitc试纸条及其制备方法和应用方法
CN108957017A (zh) * 2018-05-29 2018-12-07 郑州左安检测科技有限公司 一种检测苯二氮卓的试纸条及其制备方法和应用方法
EP3824288A1 (en) 2018-07-17 2021-05-26 Ventana Medical Systems, Inc. Materials and methods for detecting fusion proteins
CN112673258B (zh) 2018-09-13 2025-07-25 文塔纳医疗系统公司 用于检测ntrk融合蛋白的组织化学和细胞化学方法
CN112789684B (zh) 2018-10-01 2025-05-09 文塔纳医疗系统公司 用于预测对pd-1轴导向疗法的应答的方法和系统
WO2020074742A1 (en) 2018-10-12 2020-04-16 F. Hoffmann-La Roche Ag Detection methods for epitachophoresis workflow automation
JP7548903B2 (ja) 2018-11-20 2024-09-10 ヴェンタナ メディカル システムズ， インク． 形態学的特徴およびバイオマーカー発現のために細胞サンプルを調製および分析するための方法およびシステム
JP7411667B2 (ja) 2019-02-05 2024-01-11 ヴェンタナ メディカル システムズ， インク． ステージｉｖの結腸直腸がんにおける免疫細胞浸潤の評価のための方法及びシステム
WO2020229437A1 (en) 2019-05-14 2020-11-19 F. Hoffmann-La Roche Ag Devices and methods for sample analysis
WO2021041874A1 (en) 2019-08-29 2021-03-04 Martin David C Biofunctional thiophene monomers
CN115552248A (zh) 2020-05-07 2022-12-30 文塔纳医疗系统公司 用于评价肿瘤样品中egfr和egfr配体表达的组织化学系统和方法
WO2022063787A1 (en) 2020-09-22 2022-03-31 Roche Diagnostics Gmbh Antibodies specific for alpha-1,6-core-fucosylated psa and fucosylated fragments thereof
CN113552362B (zh) * 2021-07-23 2024-08-09 湖北百奥斯生物科技有限公司 一种新型信号放大的免疫荧光试剂盒
CN116444424B (zh) * 2023-06-16 2023-09-08 广东省大湾区华南理工大学聚集诱导发光高等研究院 一种基于聚集诱导发光的酪酰胺荧光材料、免疫组化染色试剂盒及其应用
CN121844210A (zh) 2023-07-07 2026-04-10 文塔纳医疗系统公司 用于评估细胞中er、pr和ki-67生物标志物的共定位的明场三重免疫组织化学测定

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0933355A1 (en) * 1997-12-24 1999-08-04 Universiteit Maastricht Preparation of tyramide conjugates
JP2008228637A (ja) * 2007-03-20 2008-10-02 Tokushima Bunri Univ 蛍光相関分光測定法を用いた過酸化水素量の測定方法及びその利用方法
JP2008298654A (ja) * 2007-05-30 2008-12-11 Ventana Medical Systems Inc バイオマーカーの多色発色検出
JP2010508532A (ja) * 2006-11-01 2010-03-18 ベンタナ・メデイカル・システムズ・インコーポレーテツド ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (de) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
EP0292202B1 (en) * 1987-05-19 1992-09-02 FISONS plc 2-(3,4-dihydroxyphenyl ethyl amines, their preparation and use as pharmaceutical compounds
DE3836656A1 (de) 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
US5455143A (en) * 1991-10-25 1995-10-03 Minnesota Mining And Manufacturing Company Aminoketone sensitizers for aqueous soluble photopolymer compositions
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6372937B1 (en) 1998-11-09 2002-04-16 Mark Norman Bobrow Enhanced catalyzed reporter deposition
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
ATE311378T1 (de) * 1999-09-17 2005-12-15 Nissan Chemical Ind Ltd Benzopyran derivate
US6630469B2 (en) * 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
DE60112742T2 (de) * 2000-05-19 2006-02-02 Applied Research Systems Ars Holding N.V. Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
WO2003092043A2 (en) 2001-07-20 2003-11-06 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
EP1627420B1 (en) 2003-05-07 2020-07-15 Indiana University Research and Technology Corporation Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
WO2005007621A2 (en) * 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
JP4411153B2 (ja) * 2003-07-18 2010-02-10 富士フイルム株式会社 ２光子吸収色素消色材料、３次元的屈折率変調材料、３次元吸収率変調材料及び３次元光記録材料
KR100657891B1 (ko) 2003-07-19 2006-12-14 삼성전자주식회사 반도체 나노결정 및 그 제조방법
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324551D0 (en) * 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US7323567B2 (en) * 2003-10-30 2008-01-29 Boehringer Ingelheim (Canada) Ltd. RSV polymerase inhibitors
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US20060246423A1 (en) 2005-02-10 2006-11-02 Adelson Martin E Method and kit for the collection and maintenance of the detectability of a plurality of microbiological species in a single gynecological sample
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
ES2548518T3 (es) 2005-11-23 2015-10-19 Ventana Medical Systems, Inc. Conjugado molecular
WO2010121963A1 (en) * 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as hsp90 inhibitors
WO2012003478A2 (en) * 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0933355A1 (en) * 1997-12-24 1999-08-04 Universiteit Maastricht Preparation of tyramide conjugates
JP2010508532A (ja) * 2006-11-01 2010-03-18 ベンタナ・メデイカル・システムズ・インコーポレーテツド ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
JP2008228637A (ja) * 2007-03-20 2008-10-02 Tokushima Bunri Univ 蛍光相関分光測定法を用いた過酸化水素量の測定方法及びその利用方法
JP2008298654A (ja) * 2007-05-30 2008-12-11 Ventana Medical Systems Inc バイオマーカーの多色発色検出

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"TYRAMIDE SIGNAL AMPLIFICATION (TSA) TECHNOLOGY", HANDBOOK OF FLUORESCENT PROBES AND RESEARCH PRODUCTS, 9TH ED., [ONLINE], JPN5013008461, 1 January 2002 (2002-01-01), ISSN: 0003012414 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10041950B2 (en) 2012-03-27 2018-08-07 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US11906523B2 (en) 2012-03-27 2024-02-20 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
JP2015514214A (ja) * 2012-03-27 2015-05-18 ヴェンタナ メディカル システムズ， インク． シグナリングコンジュゲート及び使用法
US10866234B2 (en) 2015-03-13 2020-12-15 Sysmex Corporation Method for detecting analyte
JPWO2016147825A1 (ja) * 2015-03-13 2017-12-28 シスメックス株式会社 被検物質の検出方法およびその方法に用いられる試薬キット
US11899016B2 (en) 2015-11-22 2024-02-13 Ventana Medical Systems, Inc. Methods of identifying immune cells in PD-L1 positive tumor tissue
JP2018536163A (ja) * 2015-11-22 2018-12-06 ヴェンタナ メディカル システムズ， インク． Ｐｄ−ｌ１陽性腫瘍組織における免疫細胞を同定する方法
JP2017158497A (ja) * 2016-03-10 2017-09-14 コニカミノルタ株式会社 Ｆｉｓｈ染色方法
JPWO2017175523A1 (ja) * 2016-04-06 2019-02-14 コニカミノルタ株式会社 蛍光免疫染色法
WO2017175523A1 (ja) * 2016-04-06 2017-10-12 コニカミノルタ株式会社 蛍光免疫染色法
JP2020514701A (ja) * 2016-12-19 2020-05-21 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
JP2022169540A (ja) * 2016-12-19 2022-11-09 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
JP7438281B2 (ja) 2016-12-19 2024-02-26 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
JP2022500657A (ja) * 2018-09-20 2022-01-04 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
JP7455816B2 (ja) 2018-09-20 2024-03-26 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
JP2023538753A (ja) * 2020-08-28 2023-09-11 ヴェンタナ メディカル システムズ， インク． 検出可能な部分を含むコンジュゲート
JP7848186B2 (ja) 2020-08-28 2026-04-20 ヴェンタナ メディカル システムズ， インク． 検出可能な部分を含むコンジュゲート
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本

Also Published As

Publication number Publication date
AU2011274369A1 (en) 2012-12-06
WO2012003476A3 (en) 2012-05-03
WO2012003476A2 (en) 2012-01-05
CA2800936A1 (en) 2012-01-05
EP2588443A2 (en) 2013-05-08
US20130109019A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
US20130109019A1 (en) Hapten conjugates for target detection
JP7000489B2 (ja) ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
JP6770150B2 (ja) 免疫組織化学およびｉｎ ｓｉｔｕハイブリダーゼーションのためのポリマー担体
US11906523B2 (en) Signaling conjugates and methods of use
US12173031B2 (en) Peptide nucleic acid conjugates
CA3107113A1 (en) Polymeric tandem dyes having pendant narrow emission acceptor
AU2019208215B2 (en) Haptens, hapten conjugates, compositions thereof and method for their preparation and use
JP7849883B2 (ja) 生体分子構造検出用プローブ、生体分子構造検出用キット、及び生体分子構造の検出方法
WO2024263272A2 (en) Methods and systems for sensitive and multiplexed analysis of biological samples using cleavable fluorphores and 'click' chemistry

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150721